
    
      The non-inferiority of the immunogenicity, safety, and antibody persistence of Hib-MenCY-TT
      vaccine will be compared to ActHIB®, a monovalent Hib conjugate vaccine licensed in the US.

      All subjects will be vaccinated at 2, 4, 6, and 12 to 15 months. The immunogenicity of the
      MenC and MenY antigens will be summarized.

      MenC and MenY immunogenicity will be compared to Menomune® (a quadrivalent meningococcal A,
      C, Y, and W-135 plain polysaccharide vaccine licensed in the US) administered to children 3
      to 5 years of age.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    
  